Citadel Advisors
UBX

Citadel Advisors’s Unity Biotechnology UBX Stock Holding History

Citadel Advisors’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-12,800
Closed -$4.86K – 14164
2025
Q2 		$4.86K Buy
12,800
+2,500
+24% +$2.14K ﹤0.01% 12234
2025
Q1 		$10.7K Buy
+10,300
New +$18.6K ﹤0.01% 13528
2024
Q4 		– Sell
-16,200
Closed -$23.8K – 15422
2024
Q3 		$23.8K Buy
16,200
+15,600
+2,600% +$22.9K ﹤0.01% 12642
2024
Q2 		$810 Sell
600
-3,500
-85% -$5.32K ﹤0.01% 13908
2024
Q1 		$6.72K Sell
4,100
-2,200
-35% -$3.82K ﹤0.01% 13651
2023
Q4 		$12.2K Buy
6,300
+200
+3% +$372 ﹤0.01% 13005
2023
Q3 		$14.6K Sell
6,100
-1,700
-22% -$4.5K ﹤0.01% 12863
2023
Q2 		$19.9K Sell
7,800
-4,600
-37% -$12.1K ﹤0.01% 12730
2023
Q1 		$20.2K Buy
12,400
+8,990
+264% +$36K ﹤0.01% 13062
2022
Q4 		$9.34K Buy
+3,410
New +$9.91K ﹤0.01% 13689
2022
Q3 		– Sell
-1,340
Closed -$8K – 13636
2022
Q2 		$8K Sell
1,340
-5,040
-79% -$42K ﹤0.01% 12632
2022
Q1 		$71K Sell
6,380
-2,310
-27% -$25.9K ﹤0.01% 12569
2021
Q4 		$127K Buy
8,690
+4,500
+107% +$98.3K ﹤0.01% 12470
2021
Q3 		$126K Sell
4,190
-1,040
-20% -$36.7K ﹤0.01% 12588
2021
Q2 		$243K Sell
5,230
-2,240
-30% -$108K ﹤0.01% 11758
2021
Q1 		$448K Buy
7,470
+1,180
+19% +$80.5K ﹤0.01% 9919
2020
Q4 		$330K Sell
6,290
-1,630
-21% -$78.6K ﹤0.01% 8904
2020
Q3 		$274K Buy
+7,920
New +$502K ﹤0.01% 8281

Other funds holding UBX

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
AIP
Ameritas Investment Partners Lincoln, Nebraska $3.25B AUM 28.52% 1-Year Est. Return
AWM
AllSquare Wealth Management Albany, New York $189M AUM 14.89% 1-Year Est. Return

Citadel Advisors's UBX Position: Q4 2024 in Review

Citadel Advisors sold out of Unity Biotechnology (UBX) in Q4 2024, closing a stake of 69,210 shares — an estimated $102K sold.

Citadel Advisors first reported a position in UBX in Q2 2018 and held it in 23 quarters. The position peaked at $2.64M in Q4 2019. 37 funds tracked by Wall St. Rank hold UBX as of Q4 2024.

  • Citadel Advisors reported no remaining Unity Biotechnology position as of Q4 2024 after selling out during the quarter.
  • Citadel Advisors sold 69,210 Unity Biotechnology shares in Q4 2024, an estimated $102K.
  • Citadel Advisors first reported a position in Unity Biotechnology in Q2 2018 and held it in 23 quarters.
  • Citadel Advisors's Unity Biotechnology position peaked at $2.64M in Q4 2019.
  • 37 funds tracked by Wall St. Rank held Unity Biotechnology as of Q4 2024.

Based on Citadel Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.